These Analysts Slash Their Forecasts On Conmed After Q4 Results

CONMED Corporation CNMD posted better-than-expected earnings for its fourth quarter, but issued FY25 earnings and revenue guidance below estimates.

Conmed reported quarterly earnings of $1.34 per share which beat the analyst consensus estimate of $1.20 per share. The company reported quarterly sales of $345.94 million which beat the analyst consensus estimate of $341.01 million.

“2024 was a year of solid sales and earnings growth but was also challenging as we navigated persistent supply challenges for parts of our business. I am pleased with our progress in the fourth quarter, particularly with respect to our improved profitability,” commented Patrick J. Beyer, CONMED’s President and Chief Executive Officer. “In 2025, we are laser focused on improving our operations and strengthening our foundation for future above-market revenue and profitability growth.”

Conmed said it sees FY2025 adjusted EPS of $4.25-4.40, versus market estimates of $4.74. The company expects sales of $1.344 billion-1.372 billion, versus projections of $1.40 billion.

Conmed shares gained 1.5% to close at $74.00 on Wednesday.

These analysts made changes to their price targets on Conmed following earnings announcement.

• JP Morgan analyst Robbie Marcus downgraded Conmed from Overweight to Neutral and lowered the price target from $85 to $70.
• Needham analyst Mike Matson maintained Conmed with a Buy and lowered the price target from $97 to $91..

Considering buying CNMD stock? Here’s what analysts think:

Read This Next: